Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Breast Neoplasms 45HER2-positive Breast Cancer 8Carcinoma, Non-Small-Cell Lung 5Breast Diseases 3Brain Neoplasms 3Advanced Breast Cancer 3Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Solid Tumor 1Salivary Gland Neoplasms 1Rare Tumour 1Rare Tumor 1Pathologic Complete Response 1Non Small Cell Lung 1Neoplasm Metastasis 1Neoadjuvant Treatment for HER2-positive, ER-positive Breast Cancer 1Metastatic Breast Cancer in the Brain 1Lung Neoplasms 1HER2-positive Metastatic Breast Cancer 1HER2-positive Early Breast Cancer 1HER2+ Early or Locally Advanced Breast Cancer 1HER2 Positive Metastatic Breast Cancer 1HER2 Positive Breast Cancer 1HER2 Insertion Mutation Positive Advanced NSCLC 1Estrogen Receptor-positive Breast Cancer 1Esophageal Squamous Cell Carcinoma 1Digestive System Neoplasms 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Breast Cancer Invasive 1

Interventions

pyrotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Non Small Cell Lung × pyrotinib × Clear all
NCT02834936 2025-08-28

A Clinica Study of Pyrotinib in Patients of Advanced Non-Small Cell Lung Cancer With HER2 Mutation

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Completed
60 enrolled
Thoracic

Non Small Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡